2013
DOI: 10.1016/j.hlc.2012.12.015
|View full text |Cite
|
Sign up to set email alerts
|

Choice of Valve Prosthesis in a Rare Clinical Condition: Aortic Stenosis due to Alkaptonuria

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
15
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(15 citation statements)
references
References 6 publications
0
15
0
Order By: Relevance
“…AKU is mostly asymptomatic in early life, with arthropathy and cardiovascular symptoms appearing in later decades of life. Cardiovascular involvement has been described in as many as 40% of AKU patients (mean and median age of detection being 54 and 52 years, respectively) [1]. Alkaptonuric ochronosis can be treated symptomatically during the early stages, whereas for end stages total joint and heart valve replacements may be required [1–3], but no specific cure exists at the moment, although a phase II clinical trial with nitisinone is in progress.…”
mentioning
confidence: 99%
“…AKU is mostly asymptomatic in early life, with arthropathy and cardiovascular symptoms appearing in later decades of life. Cardiovascular involvement has been described in as many as 40% of AKU patients (mean and median age of detection being 54 and 52 years, respectively) [1]. Alkaptonuric ochronosis can be treated symptomatically during the early stages, whereas for end stages total joint and heart valve replacements may be required [1–3], but no specific cure exists at the moment, although a phase II clinical trial with nitisinone is in progress.…”
mentioning
confidence: 99%
“…In one study, Lok et al 7 reported a 2-patient case series of cardiac alkaptonuria who underwent aortic valve replacement. In another study, Thakur et al 8 reported a similar case of alkaptonuric aortic valve stenosis who underwent successful aortic valve replacement as well.…”
Section: Discussionmentioning
confidence: 93%
“…Dietary restriction of tyrosine and phenylalanine is often recommended but does not significantly change the progression of the disease. Reports have suggested that biological valve prosthesis may be exposed to the same process of HGA deposition and calcification as is native valve tissue, thus adversely affecting prosthesis longevity (6). Unfortunately, the recurrence rate of ochronosis in bioprosthetic valves is yet to be reported, along with limited data on the most appropriate type of valvular replacement in such patients.…”
Section: Discussionmentioning
confidence: 99%